Imagine a biotech lab that’s been running without ever needing a budget, check-in meetings, or investor oversight. Over a million years, it’s observed, tweaked, and optimized human biology – not for profits, but simply to survive. That lab is evolution. And it’s where companies like Holoclara and farms like Chapul Farms are looking for clues, inspiration, and raw materials for the next breakthroughs in medicine and sustainable health.
Holoclara: Mining Worms’ Secret Medicine Cabinet
Holoclara is pioneering a bold strategy: harnessing molecules evolved by gut-roundworms (nematodes) that naturally interact with the human immune system. Their lead drug candidate, HC002, is a small molecule derived from worm biology, now in Phase 1 trials for eosinophilic esophagitis (EoE) – an immune disease with limited treatment options.
What’s remarkable is that Holoclara is not exposing humans to live worms, but rather identifying the molecules that worms use to modulate immune responses and synthesizing them safely. This is nature’s R&D engine: worms have co-evolved with people for millennia, “learning” how to calm certain immune reactions so they can survive. Holoclara is now translating that into drugs.
Chapul Farms & The Insect Approach: Nature’s Other Lab
Insects have long been a part of human diets in many cultures, providing protein, vitamins, and bioactive compounds – sometimes even with medicinal benefits. We’ve written before about the nutritional and cultural side of eating insects here.
While Holoclara taps into worm-derived immunomodulators, Chapul Farms works with insects but as partners in sustainability (for now) and perhaps medicine in the future. Insects produce a rich arsenal of antimicrobial peptides (AMPs) – small proteins used by insects to defend themselves against bacteria, fungi, and even viruses. Scientists are increasingly recognizing how these AMPs may be effective in situations where conventional antibiotics fail, such as in biofilm infections or antibiotic resistant bacteria.
One recent paper showed that antibacterial peptides from black soldier fly larvae (Hermetia illucens) have measurable activity against pathogens like Listeria monocytogenes, Salmonella enterica, and E. coli. Some peptide fractions disrupted cell membranes, others acted inside the bacterial cell. They even showed low toxicity to mammalian cells in preliminary tests.
Chapul Farms shares this ethos: they view insects not as simple “biomass for feed,” but as complex living systems with chemistries refined by evolution to deliver both health and environmental benefits. Just as worms evolved immune-modulating secretions, insects evolved antimicrobial peptides (AMPs) that have been field-tested for millennia through predator–prey battles, infections, and symbiosis. While Chapul Farms hasn’t yet incorporated AMPs into its business model, the team is excited about the potential. Like Holoclara, they’re educating investors on a simple truth: when it comes to designing efficient waste-to-value systems, evolution outperforms R&D – you can’t beat nature’s tech.
Why the Evolutionary Lab Matters
Here’s the core advantage both Holoclara and AMPs (insect-derived) share: time. Nature has been experimenting with human (and insect) immune systems, pathogens, and environmental pressures for millions of years. That means many of the biochemical “solutions” we are now rediscovering have been stress-tested. The “lab” of co-evolution has:
-
Selected for molecules that are stable, effective, and safe across varying conditions.
-
Produced compounds that pathogens find hard to quickly evolve resistance against – especially those that act via multiple mechanisms (membrane disruption, signaling interference, etc.).
-
Created diversity: each species, each environment, each microbe interaction has contributed to a library of molecular tools.
This is where modern drug discovery often lags behind. Traditional synthetic chemistry is powerful but tends to explore only a small portion of molecular space. Nature, by contrast, has already explored huge areas of that space through sheer diversity. Holoclara leverages this by asking: what molecules have worms evolved for peace-making with the immune system? Chapul Farms’ current work is already proof of this principle: by harnessing insects’ natural ability to turn food waste into high-value protein and soil nutrients, they’re showing how evolution’s chemistry can be adapted for sustainable, real-world systems – with future potential in health and medicine as well.
What the Science Says: AMPs, Worm Molecules, and Early Clinical Trials
Here are some of the most promising findings so far:
-
HC002 from Holoclara is now in a first-in-human Phase-1 clinical trial. The study is assessing safety, tolerability, and pharmacokinetics of this worm-derived molecule in healthy volunteers. Initial preclinical data shows activity in allergic and autoimmune disease models.
-
A major review of insect-derived AMPs (2023) highlighted more than 3,500 natural antimicrobial peptides catalogued in various insect species, including defensins, cecropins, attacins, etc. Many show activity against multidrug-resistant bacteria and biofilms – which are notoriously hard to treat with standard antibiotics.
-
The black soldier fly peptide work (2024) where certain fractions (named F2, F3 etc.) exhibited low minimum inhibitory concentrations (MICs) against key pathogens. Some fractions caused bacterial membrane disruption – the kind of broad-spectrum mechanism that makes resistance less likely.
Balancing Promise with Real-World Hurdles
No biotech fairy tale is complete without a few dragons. Here are key challenges both Holoclara and insect AMP approaches must navigate:
-
Translational gap: Moving from preclinical (animals, cell culture) to human safety and efficacy takes time, regulatory oversight, and large trials. Holoclara’s Phase 1 is a major step, but even successful early trials don’t guarantee long‐term therapeutic impact.
-
Manufacturing & consistency: Natural molecules often suffer from variability. Worms or insects raised under different conditions may produce different compounds or concentrations. Scaling up production while ensuring consistency (purity, potency, safety) is nontrivial.
-
Delivery & dosing: Worm-derived molecules must be safe when delivered orally, avoid off-target effects, have acceptable half-lives in the body, etc. For AMPs, toxicity to human cells, stability in the body, immune reactions, and cost of peptide synthesis are important constraints.
-
Regulatory and public perception: There’s still a “yuck” factor for some people, especially with worms. Regulatory agencies require strict safety data. For AMPs, novel peptides may face long review times.
-
Ecological / sustainability trade-offs: While insect farming is more sustainable than many protein sources, producing AMPs or extracting insect compounds on large scales might involve energy-intensive steps or land/waste concerns. Also, sourcing insect feed, maintaining hygiene, etc., matter.
Where Holoclara & Chapul Could Learn From Each Other
Holoclara’s worm strategy offers a roadmap for how to responsibly and cleanly turn evolutionary wisdom into human medicine. Chapul Farms’ work with insects suggests pathways for AMPs and insect bioactives—especially as food, feed, or even therapeutic adjuncts.
Here are ideas for cross-pollination:
-
Using holistic insect rearing systems to optimize health and immune profiles in insect-derived molecules (just as worm biology optimizes for immune modulation).
-
Shared clean manufacturing best practices (GMP standards) to ensure that extract-based therapies or AMPs are safe and reproducible.
-
Looking at hybrid approaches: e.g., combining insect-derived AMPs with worm-derived immunomodulators to treat complex immune conditions, or to support wound healing + resist infection + modulate inflammation.
The Big Picture: Evolution Already in the Clinic with Holoclara
Holoclara and insect AMPs point toward a future where the most mysterious biotech pipelines – the ones that feel “novel” or “wild” – are actually rediscoveries of what biology already figured out long ago. Claims like “first in class,” “orally available worm-derived small molecule,” or “peptides that kill resistant bacteria plus biofilms” are impressive not because they invent from scratch, but because they translate nature’s time-tested experiments into tools we can use more safely, scalably, and ethically.
Holoclara’s HC002 trial is expected to report results in 2025, but whether it fully succeeds or not, it opens doors. The insect AMP field is pushing in parallel: bioinformatics tools, molecular modeling, synthetic peptide design are accelerating how fast we can test, refine, and bring new molecules forward.
Conclusion: Paying Attention to What’s Been There All Along
Science often looks forward – chasing future technologies, radical inventions, disruptive platforms. But what if some of the most powerful tools are already beneath our feet, or inside our gut, or buzzing around us? Worms and insects aren’t oddities to be feared; they are treasures to learn from.
Holoclara is showing us that worm-derived therapies might become new medicines for diseases many thought hard to solve. Insects, via AMPs and related bioactive compounds, might offer the next generation of infection fighters or immune modulators. Together, they suggest a paradigm shift: innovation not from reinventing biology, but from listening to it.
References
-
“Holoclara wriggles roundworm-derived molecule into Phase 1, targeting immune disease,” Fierce Biotech (Dec 2024). Fierce Biotech
-
“Holoclara Initiates Phase 1 Clinical Trial Evaluating Worm-Derived Therapeutic HC002 in Healthy Adults,” Business Wire (Dec 2024). Business Wire
-
“Antimicrobial Peptides Derived From Insects Offer a Novel Biosource,” Frontiers in Microbiology (2021) — review of insect AMPs, anti-biofilm strategies. Frontiers
-
“Unraveling the Role of Antimicrobial Peptides in Insects,” MDPI International Journal of Molecular Sciences (2023) — overview of insect immunity, large AMP databases. MDPI
-
“Antibacterial peptides from black soldier fly (Hermetia illucens) larvae: mode of action and characterization,” Scientific Reports (2024) — specific recent study of insect AMPs. Nature